Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

Bibliographic Details
Main Authors:	Shaw, RH, Stuart, A, Greenland, M, Liu, X, Nguyen Van-Tam, JS, Snape, MD, Mujadidi, YF
Other Authors:	Com-COV Study Group
Format:	Journal article
Language:	English
Published:	Elsevier 2021

Similar Items

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine
by: Thuy Trang Nguyen, et al.
Published: (2022-03-01)

Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial
by: Shaw, RH, et al.
Published: (2022)

Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines
by: Guy Cohen, et al.
Published: (2022-11-01)

Reactogenicity after heterologous and homologous COVID-19 prime-boost vaccination regimens: descriptive interim results of a comparative observational cohort study
by: Lisette Warkentin, et al.
Published: (2022-05-01)

Heterologous Covid-19 vaccines intervention effect on reactogenicity
by: Wajeha Najeeb, et al.
Published: (2023-12-01)

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
by: Liu, X, et al.
Published: (2021)

Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women
by: Chenchit Chayachinda, et al.
Published: (2023-08-01)

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial
by: Stuart, ASV, et al.
Published: (2021)

Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study
by: Niko Kohmer, et al.
Published: (2023-03-01)

Systemic reactogenicity following homologues and heterologous prime-boost AZD1222 and BNT162b2 COVID-19 vaccination of 2862 healthcare workers compared with an unvaccinated population
by: Sorosh Tabatabaeifar, et al.
Published: (2023-04-01)

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study
by: Kriangkrai Tawinprai, et al.
Published: (2023-01-01)

Heterologous prime-boost vaccination against COVID-19: is it safe and reliable?
by: Om Prakash Choudhary, et al.
Published: (2021-12-01)

Heterologous Prime-Boost Vaccination with Commercial FMD Vaccines Elicits a Broader Immune Response than Homologous Prime-Boost Vaccination in Pigs
by: Jaejo Kim, et al.
Published: (2023-02-01)

Developing a personalized heterologous prime boost vaccination strategy for tumor therapy
by: Ramirez-Valdez, RA
Published: (2021)

DNA-based vaccines for malaria: a heterologous prime-boost immunisation strategy.
by: Hill, A, et al.
Published: (2000)

Heterologous prime-boost vaccination protects against EBV antigen-expressing lymphomas.
by: Rühl, J, et al.
Published: (2019)

Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV
by: Ros Chapman, et al.
Published: (2021-11-01)

Is heterologous prime-boost COVID-19 vaccination a concern or an opportunity for Ethiopia?
by: Tesfaye Gelanew, et al.
Published: (2023-01-01)

Exploring heterologous prime-boost vaccination approaches to enhance influenza control in pigs
by: Chong Li, et al.
Published: (2020-07-01)

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials
by: Julia L. Hurwitz, et al.
Published: (2010-02-01)

Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens
by: Verena Klemis, et al.
Published: (2022-08-01)

Immunogenicity and reactogenicity of a reduced schedule of a 4-component capsular group B meningococcal vaccine: a randomized controlled trial in infants
by: Valente Pinto, M, et al.
Published: (2020)

Complete protective immunity against blood-stage malaria induced by heterologous prime-boost vaccination
by: Draper, S, et al.
Published: (2005)

Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression
by: Ramirez-Valdez, RA, et al.
Published: (2023)

Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression
by: Ramiro A. Ramirez-Valdez, et al.
Published: (2023-06-01)

Adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations
by: Amnuay Kleebayoon, et al.
Published: (2023-05-01)

Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates
by: Qian He, et al.
Published: (2021-01-01)

Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M
by: Venkatraman, N, et al.
Published: (2017)

The Effects of Heterologous Immunization with Prime-Boost COVID-19 Vaccination against SARS-CoV-2
by: Tzu-Chuan Ho, et al.
Published: (2021-10-01)

Correlation of adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations
by: Aristine Cheng, et al.
Published: (2023-05-01)

Correlation of adverse effects and antibody responses following homologous and heterologous COVID-19 prime-boost vaccinations
by: Aristine Cheng, et al.
Published: (2023-05-01)

Immunogenicity and reactogenicity of heterologous immunization schedules with COVID-19 vaccines: a systematic review and network meta-analysis
by: Pei Li, et al.
Published: (2023-01-01)

Progress in DNA-based heterologous prime-boost immunization strategies for malaria.
by: Moore, A, et al.
Published: (2004)

Broadly Reactive IgG Responses to Heterologous H5 Prime-Boost Influenza Vaccination Are Shaped by Antigenic Relatedness to Priming Strains
by: Jiong Wang, et al.
Published: (2021-08-01)

Protection of laying chickens against the Canadian DMV/1639 infectious bronchitis virus infection through priming with heterologous live vaccine and boosting with heterologous or homologous inactivated vaccine
by: Mohamed S.H. Hassan, et al.
Published: (2024-01-01)

Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaques.
by: Rogers, W, et al.
Published: (2001)

Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers.
by: Vuola, J, et al.
Published: (2005)

835 Heterologous prime boost viral vector vaccination provides protection against intracranial syngeneic murine glioblastoma
by: Mark Gilbert, et al.
Published: (2023-11-01)

Immunogenicity and Safety of Homologous and Heterologous Prime–Boost Immunization with COVID-19 Vaccine: Systematic Review and Meta-Analysis
by: Haoyue Cheng, et al.
Published: (2022-05-01)

Heterologous prime-boost cellular vaccination induces potent antitumor immunity against triple negative breast cancer
by: Seyedeh-Raheleh Niavarani, et al.
Published: (2023-02-01)